Outcomes of LASIK retreatments after SMILE

Session Details

Session Title: SMILE, LASIK and Re-treatment

Session Date/Time: Monday 09/10/2017 | 14:30-16:00

Paper Time: 15:33

Venue: Room 2.1

First Author: : G.Carp UK

Co Author(s): :    D. Reinstein   T. Archer                 

Abstract Details

Purpose:

To report the outcomes of LASIK retreatments after SMILE.

Setting:

London Vision Clinic, London, UK

Methods:

Retrospective review of all eyes to have undergone a routine refractive retreatment by LASIK after primary SMILE at London Vision Clinic. PRK and therapeutic retreatments were not included in this analysis. Thin flap LASIK was performed if sufficient tissue was available for safe flap creation between the maximum epithelial thickness and minimum cap thickness. Otherwise, the SMILE interface was converted into a LASIK flap by Circle or sidecut only. Our multivariate nomogram for LASIK retreatments was used, including sphere, cylinder, age, and primary SEQ as variables. Patients were followed for 1 year after surgery and standard outcomes analysis was performed.

Results:

Mean attempted SEQ was -0.04±0.99D (-1.88 to +1.50D). Mean cylinder was 0.70±0.55D (0.00 to 2.25D). Postop UDVA was 20/20 or better in 83% of eyes. Mean postop SEQ relative to the target was +0.19±0.46D (-0.88 to +2.13D), with 81% within ±0.50D. Mean postop cylinder was 0.31±0.24D (0.00 to 1.00D). There was 1 line loss CDVA in 15% of eyes, but no eyes lost ≥2 lines. There was a small increase in contrast sensitivity (P<.05). Overcorrection was identified in myopic retreatments (n=20) of -1.00D or more; mean postop SEQ was +0.59±0.64D (-0.63 to +2.13D).

Conclusions:

Retreatment after SMILE by LASIK achieved excellent visual and refractive outcomes, although it appears that myopic LASIK retreatment after primary myopic SMILE requires a different nomogram than for myopic LASIK retreatment after primary myopic LASIK.

Financial Disclosure:

has significant investment interest in a company producing, developing or supplying product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented